SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thomas M. who wrote (1340)10/29/1998 3:43:00 AM
From: Bob Swift  Read Replies (1) of 10280
 
The result of the S-Oxybutynin trial is coming out soon. I wonder if a negative result may produce an outsized dip for SEPR short term. Thinking about it, it would be rather odd for both the isomers to have the same effect on urinary incontinence but through different mechanisms. The possibilities left are (1) that the S-isomer has the therapeutic effect while the R-isomer has the side effect, or (2) that the S-isomer doesn't do anything and that the R-isomer does both good and harm.If (1) is the answer then I don't understand why SEPR would need to do an escalated doses study instead of the standard dose.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News